The aim of this review is to provide an overview of the most recent findings on the effects of SGLT2 inhibitors on NAFLD biomarkers and the potential of SGLT2 inhibitors to successfully treat NAFLD. This evidence concerns the gene SLC5A2 and metabolic dysfunction-associated steatotic liver disease.